{
  "denotations": [
    {
      "id": "T2",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 75,
        "end": 80
      }
    },
    {
      "id": "T3",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 83,
        "end": 88
      }
    },
    {
      "id": "T4",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 95,
        "end": 100
      }
    },
    {
      "id": "T8",
      "obj": "Disease",
      "span": {
        "begin": 150,
        "end": 187
      }
    },
    {
      "id": "T9",
      "obj": "Chemical",
      "span": {
        "begin": 207,
        "end": 279
      }
    },
    {
      "id": "T10",
      "obj": "Chemical",
      "span": {
        "begin": 207,
        "end": 216
      }
    },
    {
      "id": "T11",
      "obj": "Chemical",
      "span": {
        "begin": 222,
        "end": 238
      }
    },
    {
      "id": "T12",
      "obj": "Chemical",
      "span": {
        "begin": 241,
        "end": 252
      }
    },
    {
      "id": "T13",
      "obj": "Chemical",
      "span": {
        "begin": 255,
        "end": 266
      }
    },
    {
      "id": "T14",
      "obj": "Chemical",
      "span": {
        "begin": 269,
        "end": 279
      }
    }
  ],
  "sourcedb": "PubMed",
  "sourceid": "20303013_3",
  "text": "In this study , we investigated the influence of the genetic polymorphisms GSTM1 , GSTT1 , and GSTP1 on treatment response in 94 Korean patients with de novo diffuse large B-cell lymphoma , who had received rituximab plus cyclophosphamide / doxorubicin / vincristine / prednisone ( R- CHOP ) as a front-line regimen ."
}
